EBV Positive is an inclusion criterion in 28 clinical trials for diffuse large B-cell lymphoma, of which 24 are open and 4 are closed. Of the trials that contain EBV Positive and diffuse large B-cell lymphoma as inclusion criteria, 5 are phase 1 (5 open), 8 are phase 1/phase 2 (6 open), 9 are phase 2 (7 open), 2 are phase 2/phase 3 (2 open), and 4 are phase 3 (4 open) [5].

EBV Positive is an inclusion criterion in 23 clinical trials for EBV-positive diffuse large B-cell lymphoma, not otherwise specified, of which 22 are open and 1 is closed. Of the trials that contain EBV Positive and EBV-positive diffuse large B-cell lymphoma, not otherwise specified as inclusion criteria, 6 are phase 1 (6 open), 7 are phase 1/phase 2 (6 open), 5 are phase 2 (5 open), 2 are phase 2/phase 3 (2 open), and 3 are phase 3 (3 open) [5].

EBV Positive is an inclusion criterion in 20 clinical trials for T-cell/histiocyte-rich large B-cell lymphoma, of which 20 are open and 0 are closed. Of the trials that contain EBV Positive and T-cell/histiocyte-rich large B-cell lymphoma as inclusion criteria, 6 are phase 1 (6 open), 3 are phase 1/phase 2 (3 open), 5 are phase 2 (5 open), 2 are phase 2/phase 3 (2 open), and 4 are phase 3 (4 open) [5].

EBV Positive is an inclusion criterion in 19 clinical trials for nasopharyngeal carcinoma, of which 15 are open and 4 are closed. Of the trials that contain EBV Positive and nasopharyngeal carcinoma as inclusion criteria, 4 are phase 1 (4 open), 4 are phase 1/phase 2 (3 open), 9 are phase 2 (6 open), 1 is phase 2/phase 3 (1 open), and 1 is phase 3 (1 open) [5].

EBV Positive is an inclusion criterion in 18 clinical trials for diffuse large B-cell lymphoma, not otherwise specified, of which 17 are open and 1 is closed. Of the trials that contain EBV Positive and diffuse large B-cell lymphoma, not otherwise specified as inclusion criteria, 6 are phase 1 (6 open), 4 are phase 1/phase 2 (3 open), 3 are phase 2 (3 open), 2 are phase 2/phase 3 (2 open), and 3 are phase 3 (3 open) [5].

EBV Positive is an inclusion criterion in 12 clinical trials for double-hit lymphoma, of which 11 are open and 1 is closed. Of the trials that contain EBV Positive and double-hit lymphoma as inclusion criteria, 2 are phase 1 (2 open), 3 are phase 1/phase 2 (2 open), 4 are phase 2 (4 open), 1 is phase 2/phase 3 (1 open), and 2 are phase 3 (2 open) [5].

EBV Positive is an inclusion criterion in 12 clinical trials for transformed non-hodgkin lymphoma, of which 11 are open and 1 is closed. Of the trials that contain EBV Positive and transformed non-hodgkin lymphoma as inclusion criteria, 4 are phase 1 (4 open), 6 are phase 1/phase 2 (5 open), 1 is phase 2/phase 3 (1 open), and 1 is phase 3 (1 open) [5].

EBV Positive is an inclusion criterion in 11 clinical trials for lymphoma, of which 6 are open and 5 are closed. Of the trials that contain EBV Positive and lymphoma as inclusion criteria, 5 are phase 1 (3 open), 3 are phase 1/phase 2 (2 open), and 3 are phase 2 (1 open) [5].

EBV Positive is an inclusion criterion in 10 clinical trials for high grade B-cell lymphoma, not otherwise specified, of which 10 are open and 0 are closed. Of the trials that contain EBV Positive and high grade B-cell lymphoma, not otherwise specified as inclusion criteria, 3 are phase 1 (3 open), 1 is phase 1/phase 2 (1 open), 4 are phase 2 (4 open), 1 is phase 2/phase 3 (1 open), and 1 is phase 3 (1 open) [5].

EBV Positive is an inclusion criterion in 10 clinical trials for triple-hit lymphoma, of which 9 are open and 1 is closed. Of the trials that contain EBV Positive and triple-hit lymphoma as inclusion criteria, 2 are phase 1 (2 open), 3 are phase 1/phase 2 (2 open), 4 are phase 2 (4 open), and 1 is phase 2/phase 3 (1 open) [5].

EBV Positive is an inclusion criterion in 9 clinical trials for primary mediastinal B-cell lymphoma, of which 9 are open and 0 are closed. Of the trials that contain EBV Positive and primary mediastinal B-cell lymphoma as inclusion criteria, 5 are phase 1 (5 open), 1 is phase 1/phase 2 (1 open), 1 is phase 2 (1 open), and 2 are phase 3 (2 open) [5].

EBV Positive is an inclusion criterion in 8 clinical trials for diffuse large B-cell lymphoma associated with chronic inflammation, of which 8 are open and 0 are closed. Of the trials that contain EBV Positive and diffuse large B-cell lymphoma associated with chronic inflammation as inclusion criteria, 4 are phase 1 (4 open), 1 is phase 1/phase 2 (1 open), 1 is phase 2 (1 open), 1 is phase 2/phase 3 (1 open), and 1 is phase 3 (1 open) [5].

EBV Positive is an inclusion criterion in 8 clinical trials for post-transplant lymphoproliferative disorder, of which 5 are open and 3 are closed. Of the trials that contain EBV Positive and post-transplant lymphoproliferative disorder as inclusion criteria, 1 is early phase 1 (1 open), 5 are phase 2 (3 open), and 2 are phase 3 (1 open) [5].

EBV Positive is an inclusion criterion in 8 clinical trials for primary cutaneous diffuse large B-cell lymphoma, leg type, of which 8 are open and 0 are closed. Of the trials that contain EBV Positive and primary cutaneous diffuse large B-cell lymphoma, leg type as inclusion criteria, 1 is phase 1 (1 open), 2 are phase 1/phase 2 (2 open), 2 are phase 2 (2 open), 1 is phase 2/phase 3 (1 open), and 2 are phase 3 (2 open) [5].

EBV Positive is an inclusion criterion in 7 clinical trials for ALK-positive large B-cell lymphoma, of which 7 are open and 0 are closed. Of the trials that contain EBV Positive and ALK-positive large B-cell lymphoma as inclusion criteria, 2 are phase 1 (2 open), 2 are phase 1/phase 2 (2 open), 2 are phase 2 (2 open), and 1 is phase 3 (1 open) [5].

EBV Positive is an inclusion criterion in 7 clinical trials for grade 3b follicular lymphoma, of which 7 are open and 0 are closed. Of the trials that contain EBV Positive and grade 3b follicular lymphoma as inclusion criteria, 4 are phase 1/phase 2 (4 open), 1 is phase 2/phase 3 (1 open), and 2 are phase 3 (2 open) [5].

EBV Positive is an inclusion criterion in 6 clinical trials for gastric carcinoma, of which 5 are open and 1 is closed. Of the trials that contain EBV Positive and gastric carcinoma as inclusion criteria, 1 is phase 1 (1 open), 3 are phase 1/phase 2 (3 open), and 2 are phase 2 (1 open) [5].

EBV Positive is an inclusion criterion in 6 clinical trials for high grade B-cell lymphoma with MYC and BCL2 and/or BCL6 rearrangements, of which 6 are open and 0 are closed. Of the trials that contain EBV Positive and high grade B-cell lymphoma with MYC and BCL2 and/or BCL6 rearrangements as inclusion criteria, 1 is phase 1 (1 open), 2 are phase 1/phase 2 (2 open), 1 is phase 2/phase 3 (1 open), and 2 are phase 3 (2 open) [5].

EBV Positive is an inclusion criterion in 6 clinical trials for hodgkin lymphoma, of which 3 are open and 3 are closed. Of the trials that contain EBV Positive and hodgkin lymphoma as inclusion criteria, 3 are phase 1 (2 open) and 3 are phase 2 (1 open) [5].

EBV Positive is an inclusion criterion in 5 clinical trials for B-cell non-hodgkin lymphoma, of which 5 are open and 0 are closed. Of the trials that contain EBV Positive and B-cell non-hodgkin lymphoma as inclusion criteria, 3 are phase 1 (3 open), 1 is phase 1/phase 2 (1 open), and 1 is phase 2 (1 open) [5].

EBV Positive is an inclusion criterion in 5 clinical trials for HHV8-positive diffuse large B-cell lymphoma, not otherwise specified, of which 5 are open and 0 are closed. Of the trials that contain EBV Positive and HHV8-positive diffuse large B-cell lymphoma, not otherwise specified as inclusion criteria, 3 are phase 2 (3 open), 1 is phase 2/phase 3 (1 open), and 1 is phase 3 (1 open) [5].

EBV Positive is an inclusion criterion in 5 clinical trials for mediastinal large B-cell lymphoma, of which 4 are open and 1 is closed. Of the trials that contain EBV Positive and mediastinal large B-cell lymphoma as inclusion criteria, 2 are phase 1 (2 open), 2 are phase 1/phase 2 (1 open), and 1 is phase 2 (1 open) [5].

EBV Positive is an inclusion criterion in 5 clinical trials for non-hodgkin lymphoma, of which 4 are open and 1 is closed. Of the trials that contain EBV Positive and non-hodgkin lymphoma as inclusion criteria, 3 are phase 1 (2 open), 1 is phase 1/phase 2 (1 open), and 1 is phase 2 (1 open) [5].

EBV Positive is an inclusion criterion in 4 clinical trials for cancer, of which 0 are open and 4 are closed. Of the trials that contain EBV Positive and cancer as inclusion criteria, 1 is early phase 1 (0 open), 1 is phase 1 (0 open), and 2 are phase 2 (0 open) [5].

EBV Positive is an inclusion criterion in 4 clinical trials for germinal center B-cell-like diffuse large B-cell lymphoma, of which 4 are open and 0 are closed. Of the trials that contain EBV Positive and germinal center B-cell-like diffuse large B-cell lymphoma as inclusion criteria, 2 are phase 2 (2 open), 1 is phase 2/phase 3 (1 open), and 1 is phase 3 (1 open) [5].

EBV Positive is an inclusion criterion in 4 clinical trials for head and neck squamous cell carcinoma, of which 4 are open and 0 are closed. Of the trials that contain EBV Positive and head and neck squamous cell carcinoma as inclusion criteria, 1 is phase 1 (1 open), 1 is phase 1/phase 2 (1 open), and 2 are phase 2 (2 open) [5].

EBV Positive is an inclusion criterion in 4 clinical trials for leiomyosarcoma, of which 3 are open and 1 is closed. Of the trials that contain EBV Positive and leiomyosarcoma as inclusion criteria, 2 are phase 1 (2 open) and 2 are phase 2 (1 open) [5].

EBV Positive is an inclusion criterion in 4 clinical trials for lymphoproliferative disorder, of which 3 are open and 1 is closed. Of the trials that contain EBV Positive and lymphoproliferative disorder as inclusion criteria, 2 are phase 1 (1 open), 1 is phase 1/phase 2 (1 open), and 1 is phase 2 (1 open) [5].

EBV Positive is an inclusion criterion in 4 clinical trials for malignant solid tumor, of which 4 are open and 0 are closed. Of the trials that contain EBV Positive and malignant solid tumor as inclusion criteria, 1 is phase 1 (1 open) and 3 are phase 2 (3 open) [5].

EBV Positive is an inclusion criterion in 4 clinical trials for mature T-cell and NK-cell lymphoma/leukemia, of which 3 are open and 1 is closed. Of the trials that contain EBV Positive and mature T-cell and NK-cell lymphoma/leukemia as inclusion criteria, 3 are phase 1 (3 open) and 1 is phase 2 (0 open) [5].

EBV Positive is an inclusion criterion in 4 clinical trials for nasal type extranodal NK/T-cell lymphoma, of which 2 are open and 2 are closed. Of the trials that contain EBV Positive and nasal type extranodal NK/T-cell lymphoma as inclusion criteria, 1 is phase 1/phase 2 (0 open) and 3 are phase 2 (2 open) [5].

EBV Positive is an inclusion criterion in 3 clinical trials for B-cell lymphoma, unclassifiable, with features intermediate between diffuse large B-cell lymphoma and classical hodgkin lymphoma, of which 3 are open and 0 are closed. Of the trials that contain EBV Positive and B-cell lymphoma, unclassifiable, with features intermediate between diffuse large B-cell lymphoma and classical hodgkin lymphoma as inclusion criteria, 2 are phase 1 (2 open) and 1 is phase 2 (1 open) [5].

EBV Positive is an inclusion criterion in 3 clinical trials for cervical carcinoma, of which 3 are open and 0 are closed. Of the trials that contain EBV Positive and cervical carcinoma as inclusion criteria, 2 are phase 1 (2 open) and 1 is phase 1/phase 2 (1 open) [5].

EBV Positive is an inclusion criterion in 3 clinical trials for diffuse large B-cell lymphoma activated B-cell type, of which 3 are open and 0 are closed. Of the trials that contain EBV Positive and diffuse large B-cell lymphoma activated B-cell type as inclusion criteria, 2 are phase 2 (2 open) and 1 is phase 2/phase 3 (1 open) [5].

EBV Positive is an inclusion criterion in 3 clinical trials for head and neck carcinoma, of which 3 are open and 0 are closed. Of the trials that contain EBV Positive and head and neck carcinoma as inclusion criteria, 2 are phase 1 (2 open) and 1 is phase 2 (1 open) [5].

EBV Positive is an inclusion criterion in 3 clinical trials for intravascular large B-cell lymphoma, of which 3 are open and 0 are closed. Of the trials that contain EBV Positive and intravascular large B-cell lymphoma as inclusion criteria, 1 is phase 1 (1 open), 1 is phase 2 (1 open), and 1 is phase 2/phase 3 (1 open) [5].

EBV Positive is an inclusion criterion in 3 clinical trials for lymphomatoid granulomatosis, of which 3 are open and 0 are closed. Of the trials that contain EBV Positive and lymphomatoid granulomatosis as inclusion criteria, 1 is phase 1 (1 open) and 2 are phase 2 (2 open) [5].

EBV Positive is an inclusion criterion in 3 clinical trials for non-small cell lung carcinoma, of which 3 are open and 0 are closed. Of the trials that contain EBV Positive and non-small cell lung carcinoma as inclusion criteria, 2 are phase 1 (2 open) and 1 is phase 2 (1 open) [5].

EBV Positive is an inclusion criterion in 3 clinical trials for Richter syndrome, of which 2 are open and 1 is closed. Of the trials that contain EBV Positive and Richter syndrome as inclusion criteria, 2 are phase 1 (2 open) and 1 is phase 1/phase 2 (0 open) [5].

EBV Positive is an inclusion criterion in 2 clinical trials for acute lymphoblastic leukemia, of which 2 are open and 0 are closed. Of the trials that contain EBV Positive and acute lymphoblastic leukemia as inclusion criteria, 2 are phase 1 (2 open) [5].

EBV Positive is an inclusion criterion in 2 clinical trials for bladder carcinoma, of which 2 are open and 0 are closed. Of the trials that contain EBV Positive and bladder carcinoma as inclusion criteria, 1 is phase 1 (1 open) and 1 is phase 2 (1 open) [5].

EBV Positive is an inclusion criterion in 2 clinical trials for chronic lymphocytic leukemia, of which 2 are open and 0 are closed. Of the trials that contain EBV Positive and chronic lymphocytic leukemia as inclusion criteria, 1 is phase 1 (1 open) and 1 is phase 1/phase 2 (1 open) [5].

EBV Positive is an inclusion criterion in 2 clinical trials for follicular lymphoma, of which 2 are open and 0 are closed. Of the trials that contain EBV Positive and follicular lymphoma as inclusion criteria, 1 is phase 1 (1 open) and 1 is phase 1/phase 2 (1 open) [5].

EBV Positive is an inclusion criterion in 2 clinical trials for mantle cell lymphoma, of which 2 are open and 0 are closed. Of the trials that contain EBV Positive and mantle cell lymphoma as inclusion criteria, 1 is phase 1 (1 open) and 1 is phase 1/phase 2 (1 open) [5].

EBV Positive is an inclusion criterion in 2 clinical trials for marginal zone lymphoma, of which 2 are open and 0 are closed. Of the trials that contain EBV Positive and marginal zone lymphoma as inclusion criteria, 1 is phase 1/phase 2 (1 open) and 1 is phase 2/phase 3 (1 open) [5].

EBV Positive is an inclusion criterion in 2 clinical trials for melanoma, of which 2 are open and 0 are closed. Of the trials that contain EBV Positive and melanoma as inclusion criteria, 1 is phase 1 (1 open) and 1 is phase 2 (1 open) [5].

EBV Positive is an inclusion criterion in 2 clinical trials for Merkel cell carcinoma, of which 2 are open and 0 are closed. Of the trials that contain EBV Positive and Merkel cell carcinoma as inclusion criteria, 1 is phase 1 (1 open) and 1 is phase 1/phase 2 (1 open) [5].

EBV Positive is an inclusion criterion in 2 clinical trials for plasmablastic lymphoma, of which 2 are open and 0 are closed. Of the trials that contain EBV Positive and plasmablastic lymphoma as inclusion criteria, 2 are phase 2 (2 open) [5].

EBV Positive is an inclusion criterion in 2 clinical trials for primary central nervous system lymphoma, of which 2 are open and 0 are closed. Of the trials that contain EBV Positive and primary central nervous system lymphoma as inclusion criteria, 1 is phase 1/phase 2 (1 open) and 1 is phase 2 (1 open) [5].

EBV Positive is an inclusion criterion in 2 clinical trials for primary effusion lymphoma, of which 2 are open and 0 are closed. Of the trials that contain EBV Positive and primary effusion lymphoma as inclusion criteria, 1 is phase 1 (1 open) and 1 is phase 2 (1 open) [5].

EBV Positive is an inclusion criterion in 2 clinical trials for systemic EBV-positive T-cell lymphoma of childhood, of which 2 are open and 0 are closed. Of the trials that contain EBV Positive and systemic EBV-positive T-cell lymphoma of childhood as inclusion criteria, 1 is phase 1 (1 open) and 1 is phase 1/phase 2 (1 open) [5].

EBV Positive is an inclusion criterion in 2 clinical trials for vaginal carcinoma, of which 2 are open and 0 are closed. Of the trials that contain EBV Positive and vaginal carcinoma as inclusion criteria, 1 is phase 1 (1 open) and 1 is phase 1/phase 2 (1 open) [5].

EBV Positive is an inclusion criterion in 2 clinical trials for vulvar carcinoma, of which 2 are open and 0 are closed. Of the trials that contain EBV Positive and vulvar carcinoma as inclusion criteria, 1 is phase 1 (1 open) and 1 is phase 1/phase 2 (1 open) [5].

EBV Positive is an inclusion criterion in 1 clinical trial for adenocarcinoma of the gastroesophageal junction, of which 1 is open and 0 are closed. Of the trial that contains EBV Positive and adenocarcinoma of the gastroesophageal junction as inclusion criteria, 1 is phase 1/phase 2 (1 open) [5].

EBV Positive is an inclusion criterion in 1 clinical trial for anal carcinoma, of which 1 is open and 0 are closed. Of the trial that contains EBV Positive and anal carcinoma as inclusion criteria, 1 is phase 1 (1 open) [5].

EBV Positive is an inclusion criterion in 1 clinical trial for anal squamous cell carcinoma, of which 1 is open and 0 are closed. Of the trial that contains EBV Positive and anal squamous cell carcinoma as inclusion criteria, 1 is phase 2 (1 open) [5].

EBV Positive is an inclusion criterion in 1 clinical trial for anaplastic large cell lymphoma, ALK-positive, of which 1 is open and 0 are closed. Of the trial that contains EBV Positive and anaplastic large cell lymphoma, ALK-positive as inclusion criteria, 1 is phase 1/phase 2 (1 open) [5].

EBV Positive is an inclusion criterion in 1 clinical trial for angioimmunoblastic T-cell lymphoma, of which 1 is open and 0 are closed. Of the trial that contains EBV Positive and angioimmunoblastic T-cell lymphoma as inclusion criteria, 1 is phase 2 (1 open) [5].

EBV Positive is an inclusion criterion in 1 clinical trial for appendix carcinoma, of which 1 is open and 0 are closed. Of the trial that contains EBV Positive and appendix carcinoma as inclusion criteria, 1 is phase 1 (1 open) [5].

EBV Positive is an inclusion criterion in 1 clinical trial for atypical Burkitt/Burkitt-like lymphoma, of which 1 is open and 0 are closed. Of the trial that contains EBV Positive and atypical Burkitt/Burkitt-like lymphoma as inclusion criteria, 1 is phase 2 (1 open) [5].

EBV Positive is an inclusion criterion in 1 clinical trial for B-cell acute lymphoblastic leukemia, of which 1 is open and 0 are closed. Of the trial that contains EBV Positive and B-cell acute lymphoblastic leukemia as inclusion criteria, 1 is phase 1 (1 open) [5].

EBV Positive is an inclusion criterion in 1 clinical trial for biliary tract carcinoma, of which 1 is open and 0 are closed. Of the trial that contains EBV Positive and biliary tract carcinoma as inclusion criteria, 1 is phase 2 (1 open) [5].

EBV Positive is an inclusion criterion in 1 clinical trial for breast carcinoma, of which 1 is open and 0 are closed. Of the trial that contains EBV Positive and breast carcinoma as inclusion criteria, 1 is phase 2 (1 open) [5].

EBV Positive is an inclusion criterion in 1 clinical trial for Burkitt lymphoma, of which 1 is open and 0 are closed. Of the trial that contains EBV Positive and Burkitt lymphoma as inclusion criteria, 1 is phase 2 (1 open) [5].

EBV Positive is an inclusion criterion in 1 clinical trial for central nervous system lymphoma, of which 1 is open and 0 are closed. Of the trial that contains EBV Positive and central nervous system lymphoma as inclusion criteria, 1 is phase 1/phase 2 (1 open) [5].

EBV Positive is an inclusion criterion in 1 clinical trial for cervical squamous cell carcinoma, of which 1 is open and 0 are closed. Of the trial that contains EBV Positive and cervical squamous cell carcinoma as inclusion criteria, 1 is phase 2 (1 open) [5].

EBV Positive is an inclusion criterion in 1 clinical trial for colorectal carcinoma, of which 1 is open and 0 are closed. Of the trial that contains EBV Positive and colorectal carcinoma as inclusion criteria, 1 is phase 1 (1 open) [5].

EBV Positive is an inclusion criterion in 1 clinical trial for composite lymphoma, of which 1 is open and 0 are closed. Of the trial that contains EBV Positive and composite lymphoma as inclusion criteria, 1 is phase 2/phase 3 (1 open) [5].

EBV Positive is an inclusion criterion in 1 clinical trial for EBV-positive mucocutaneous ulcer, of which 1 is open and 0 are closed. Of the trial that contains EBV Positive and EBV-positive mucocutaneous ulcer as inclusion criteria, 1 is phase 2 (1 open) [5].

EBV Positive is an inclusion criterion in 1 clinical trial for esophageal squamous cell carcinoma, of which 1 is open and 0 are closed. Of the trial that contains EBV Positive and esophageal squamous cell carcinoma as inclusion criteria, 1 is phase 1 (1 open) [5].

EBV Positive is an inclusion criterion in 1 clinical trial for extranodal marginal zone lymphoma of mucosa-associated lymphoid tissue, of which 1 is open and 0 are closed. Of the trial that contains EBV Positive and extranodal marginal zone lymphoma of mucosa-associated lymphoid tissue as inclusion criteria, 1 is phase 1 (1 open) [5].

EBV Positive is an inclusion criterion in 1 clinical trial for follicular dendritic cell sarcoma, of which 1 is open and 0 are closed. Of the trial that contains EBV Positive and follicular dendritic cell sarcoma as inclusion criteria, 1 is phase 2 (1 open) [5].

EBV Positive is an inclusion criterion in 1 clinical trial for gastric adenocarcinoma, of which 1 is open and 0 are closed. Of the trial that contains EBV Positive and gastric adenocarcinoma as inclusion criteria, 1 is phase 2 (1 open) [5].

EBV Positive is an inclusion criterion in 1 clinical trial for hemophagocytic lymphohistiocytosis, of which 1 is open and 0 are closed. Of the trial that contains EBV Positive and hemophagocytic lymphohistiocytosis as inclusion criteria, 1 is phase 2 (1 open) [5].

EBV Positive is an inclusion criterion in 1 clinical trial for hepatocellular carcinoma, of which 1 is open and 0 are closed. Of the trial that contains EBV Positive and hepatocellular carcinoma as inclusion criteria, 1 is phase 1 (1 open) [5].

EBV Positive is an inclusion criterion in 1 clinical trial for histiocytic sarcoma, of which 1 is open and 0 are closed. Of the trial that contains EBV Positive and histiocytic sarcoma as inclusion criteria, 1 is phase 2 (1 open) [5].

EBV Positive is an inclusion criterion in 1 clinical trial for immunodeficiency-associated lymphoproliferative disorder, of which 1 is open and 0 are closed. Of the trial that contains EBV Positive and immunodeficiency-associated lymphoproliferative disorder as inclusion criteria, 1 is phase 2 (1 open) [5].

EBV Positive is an inclusion criterion in 1 clinical trial for interdigitating dendritic cell sarcoma, of which 1 is open and 0 are closed. Of the trial that contains EBV Positive and interdigitating dendritic cell sarcoma as inclusion criteria, 1 is phase 2 (1 open) [5].

EBV Positive is an inclusion criterion in 1 clinical trial for Kaposi sarcoma, of which 1 is open and 0 are closed. Of the trial that contains EBV Positive and Kaposi sarcoma as inclusion criteria, 1 is phase 1 (1 open) [5].

EBV Positive is an inclusion criterion in 1 clinical trial for large B-cell lymphoma with IRF4 rearrangement, of which 1 is open and 0 are closed. Of the trial that contains EBV Positive and large B-cell lymphoma with IRF4 rearrangement as inclusion criteria, 1 is phase 1 (1 open) [5].

EBV Positive is an inclusion criterion in 1 clinical trial for malignant pleural mesothelioma, of which 1 is open and 0 are closed. Of the trial that contains EBV Positive and malignant pleural mesothelioma as inclusion criteria, 1 is phase 1 (1 open) [5].

EBV Positive is an inclusion criterion in 1 clinical trial for nodal marginal zone lymphoma, of which 1 is open and 0 are closed. Of the trial that contains EBV Positive and nodal marginal zone lymphoma as inclusion criteria, 1 is phase 1 (1 open) [5].

EBV Positive is an inclusion criterion in 1 clinical trial for pancreatic carcinoma, of which 1 is open and 0 are closed. Of the trial that contains EBV Positive and pancreatic carcinoma as inclusion criteria, 1 is phase 2 (1 open) [5].

EBV Positive is an inclusion criterion in 1 clinical trial for penile carcinoma, of which 1 is open and 0 are closed. Of the trial that contains EBV Positive and penile carcinoma as inclusion criteria, 1 is phase 1 (1 open) [5].

EBV Positive is an inclusion criterion in 1 clinical trial for peripheral T-cell lymphoma, of which 1 is open and 0 are closed. Of the trial that contains EBV Positive and peripheral T-cell lymphoma as inclusion criteria, 1 is phase 2 (1 open) [5].

EBV Positive is an inclusion criterion in 1 clinical trial for prostate carcinoma, of which 1 is open and 0 are closed. Of the trial that contains EBV Positive and prostate carcinoma as inclusion criteria, 1 is phase 1 (1 open) [5].

EBV Positive is an inclusion criterion in 1 clinical trial for sarcoma, of which 1 is open and 0 are closed. Of the trial that contains EBV Positive and sarcoma as inclusion criteria, 1 is phase 2 (1 open) [5].

EBV Positive is an inclusion criterion in 1 clinical trial for small lymphocytic lymphoma, of which 1 is open and 0 are closed. Of the trial that contains EBV Positive and small lymphocytic lymphoma as inclusion criteria, 1 is phase 1/phase 2 (1 open) [5].

EBV Positive is an inclusion criterion in 1 clinical trial for smooth muscle neoplasm, of which 1 is open and 0 are closed. Of the trial that contains EBV Positive and smooth muscle neoplasm as inclusion criteria, 1 is phase 1 (1 open) [5].

EBV Positive is an inclusion criterion in 1 clinical trial for soft tissue sarcoma, of which 1 is open and 0 are closed. Of the trial that contains EBV Positive and soft tissue sarcoma as inclusion criteria, 1 is phase 1 (1 open) [5].

EBV Positive is an inclusion criterion in 1 clinical trial for splenic marginal zone lymphoma, of which 1 is open and 0 are closed. Of the trial that contains EBV Positive and splenic marginal zone lymphoma as inclusion criteria, 1 is phase 1 (1 open) [5].

EBV Positive is an inclusion criterion in 1 clinical trial for squamous cell carcinoma of unknown primary, of which 1 is open and 0 are closed. Of the trial that contains EBV Positive and squamous cell carcinoma of unknown primary as inclusion criteria, 1 is phase 2 (1 open) [5].

EBV Positive is an inclusion criterion in 1 clinical trial for squamous cell carcinoma of the penis, of which 1 is open and 0 are closed. Of the trial that contains EBV Positive and squamous cell carcinoma of the penis as inclusion criteria, 1 is phase 2 (1 open) [5].

EBV Positive is an inclusion criterion in 1 clinical trial for T-cell non-hodgkin lymphoma, of which 1 is open and 0 are closed. Of the trial that contains EBV Positive and T-cell non-hodgkin lymphoma as inclusion criteria, 1 is phase 2 (1 open) [5].

EBV Positive is an inclusion criterion in 1 clinical trial for urothelial carcinoma, of which 1 is open and 0 are closed. Of the trial that contains EBV Positive and urothelial carcinoma as inclusion criteria, 1 is phase 1 (1 open) [5].

EBV Positive is an inclusion criterion in 1 clinical trial for vulvar/vaginal squamous cell carcinoma, of which 1 is open and 0 are closed. Of the trial that contains EBV Positive and vulvar/vaginal squamous cell carcinoma as inclusion criteria, 1 is phase 2 (1 open) [5].